Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors

25 Jun 2019

Abstract excerpt

One of the most common malignancies in men is prostate cancer, for which androgen deprivation is the standard therapy. However, prostate cancer cells become insensitive to anti-androgen treatment and proceed to a castration-resistant state with limited therapeutic options. Therefore, besides the androgen deprivation approach, novel biomarkers are urgently required for specific targeting in this deadly disease....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31242618
DOI: 10.3390/ijms20123100

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-InhibitorsPMID 31242618Read ↗

PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage SignaturesSemantic proximity Read ↗

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate CancerSemantic proximity Read ↗

PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical DevelopmentSemantic proximity Read ↗

PARP inhibitors for homologous recombination-deficient prostate cancer.Semantic proximity Read ↗

PARP Inhibitors in the Treatment of Prostate Cancer: From Scientific Rationale to Clinical DevelopmentSemantic proximity Read ↗

Prostate cancer and PARP inhibitors: progress and challengesSemantic proximity Read ↗

Changing the History of Prostate Cancer with New Targeted TherapiesSemantic proximity Read ↗

PARP inhibitors for prostate cancerSemantic proximity Read ↗

BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations.Semantic proximity Read ↗

DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic OpportunitiesSemantic proximity Read ↗

Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value.Semantic proximity Read ↗

DNA repair defects in prostate cancer: impact for screening, prognostication and treatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.